

# Fundamentals of Clinical Trials

Lawrence M. Friedman • Curt D. Furberg  
David L. DeMets • David M. Reboussin  
Christopher B. Granger

# Fundamentals of Clinical Trials

Fifth Edition

 Springer

Lawrence M. Friedman  
North Bethesda, MD, USA

David L. DeMets  
Department Biostatistics and Medical  
Informatics  
University of Wisconsin  
Madison, WI, USA

Christopher B. Granger  
Department of Medicine  
Duke University  
Durham, NC, USA

Curt D. Furberg  
Division of Public Health Sciences  
Wake Forest School of Medicine  
Winston-Salem, NC, USA

David M. Reboussin  
Department of Biostatistics  
Wake Forest School of Medicine  
Winston-Salem, NC, USA

ISBN 978-3-319-18538-5

ISBN 978-3-319-18539-2 (eBook)

DOI 10.1007/978-3-319-18539-2

Library of Congress Control Number: 2015942127

Springer Cham Heidelberg New York Dordrecht London

© Springer International Publishing Switzerland 2015

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

Springer International Publishing AG Switzerland is part of Springer Science+Business Media  
(www.springer.com)

## About the Authors

**Lawrence M. Friedman** received his M.D. from the University of Pittsburgh. After training in internal medicine, he went to the National Heart, Lung, and Blood Institute of the National Institutes of Health. During his many years there, Dr. Friedman was involved in numerous clinical trials and epidemiology studies, having major roles in their design, management, and monitoring. While at the NIH and subsequently, he served as a consultant on clinical trials to various NIH institutes and to other governmental and nongovernmental organizations. Dr. Friedman has been a member of many data monitoring and other safety committees.

**Curt D. Furberg** is Professor Emeritus of the Division of Public Health Sciences of the Wake Forest University School of Medicine. He received his M.D. and Ph.D. at the University of Umea, Sweden, and is a former chief, Clinical Trials Branch and Associate Director, Clinical Applications and Prevention Program, National Heart, Lung, and Blood Institute. Dr. Furberg established the Department of Public Health Sciences and served as its chair from 1986 to 1999. He has played major scientific and administrative roles in numerous multicenter clinical trials and has served in a consultative or advisory capacity on others. Dr. Furberg's research activities include the areas of clinical trials methodology and cardiovascular epidemiology. He is actively involved in the debate about the need for better documentation of meaningful clinical efficacy and long-term safety for drugs intended for chronic use.

**David L. DeMets, Ph.D.**, is currently the Max Halperin Professor of Biostatistics and former Chair of the Department of Biostatistics and Medical Informatics at the University of Wisconsin—Madison. He has co-authored numerous papers on statistical methods and four texts on clinical trials, two specifically on data monitoring. He has served on many NIH and industry-sponsored data monitoring committees for clinical trials in diverse disciplines. He served on the Board of Directors of the American Statistical Association, as well as having been President of the Society

for Clinical Trials and President of the Eastern North American Region (ENAR) of the Biometric Society. In addition he was Elected Fellow of the International Statistics Institute, the American Statistical Association, the Association for the Advancement of Science, the Society for Clinical Trials and the American Medical Informatics Association. In 2013, he was elected as a member of the Institute of Medicine.

**David M. Reboussin** is a Professor in the Department of Biostatistical Science at the Wake Forest University School of Medicine, where he has worked since 1992. He has a master's degree in Statistics from the University of Chicago and received his doctorate in Statistics from the University of Wisconsin at Madison. He is currently Principal Investigator for the Systolic Blood Pressure Intervention Trial Coordinating Center and has been a co-investigator in the coordinating centers for several NIH and industry funded clinical trials including Action to Control Cardiovascular Risk in Diabetes (ACCORD), Action for Health in Diabetes (Look AHEAD), the Combined Oral and Nutritional Treatment of Late-Onset Diabetes Trial (CONTROL DM) and the Estrogen Replacement and Atherosclerosis (ERA) Trial. Dr. Reboussin has served on the data and safety monitoring boards for many National Institutes of Health trials within areas including cardiology, diabetes, nephrology, pulmonology, liver disease, psychiatry, pediatrics, weight loss and smoking cessation. His work in statistical methodology has included techniques and software for sequential monitoring of clinical trials.

**Christopher B. Granger** is Professor of Medicine at Duke University, where he is an active clinical cardiologist and a clinical trialist at the Duke Clinical Research Institute. He received his M.D. at University of Connecticut and his residency training at the University of Colorado. He has had Steering Committee, academic leadership, and operational responsibilities for many clinical trials in cardiology. He has been on numerous data monitoring committees. He serves on the National Heart, Lung, and Blood Institute Board of External Experts. He works with the Clinical Trials Transformation Initiative, a partnership between the U.S. Food and Drug Administration and Duke aiming to increase the quality and efficiency of clinical trials. He is a founding member of the Sensible Guidelines for the Conduct of Clinical Trials group, a collaboration between McMaster, Oxford, and Duke Universities.

# Preface

The clinical trial is “the most definitive tool for evaluation of the applicability of clinical research.” It represents “a key research activity with the potential to improve the quality of health care and control costs through careful comparison of alternative treatments” [1]. It has been called on many occasions, “the gold standard” against which all other clinical research is measured.

Although many clinical trials are of high quality, a careful reader of the medical literature will notice that a large number have deficiencies in design, conduct, analysis, presentation, and/or interpretation of results. Improvements have occurred over the past few decades, but too many trials are still conducted without adequate attention to the fundamental principles. Certainly, numerous studies could have been improved if the authors had had a better understanding of the fundamentals.

Since the publication of the first edition of this book in 1981, a large number of other texts on clinical trials have appeared, most of which are indicated here [2–21]. Several of them, however, discuss only specific issues involved in clinical trials. Additionally, many are no longer current. The purpose of this fifth edition is to update areas in which major progress has been made since the publication of the fourth edition. We have revised most chapters considerably. Because it was becoming unwieldy, we divided the chapter on monitoring response variables into two chapters, one on monitoring committees and the other on monitoring approaches. We also added a chapter on regulatory issues.

Importantly, two new authors are now involved. This brings fresh perspectives to a book originally published over three decades ago.

In this book, we hope to assist investigators in improving the quality of their clinical trials by discussing fundamental concepts with examples from our experience and the literature. The book is intended both for investigators with some clinical trial experience and for those who plan to conduct a trial for the first time. It is also intended to be used in the teaching of clinical trial methodology and to assist members of the scientific and medical community who wish to evaluate and interpret published reports of trials. Although not a technically oriented book, it may be used

as a reference for graduate courses in clinical trials. Those readers who wish to consult more technical books and articles are provided with the relevant literature.

Because of the considerable differences in background and objectives of the intended readership, we have not attempted to provide exercises at the end of each chapter. We have, however, found two exercises to be quite useful and that apply most of the fundamental principles of this text. First, ask students to critique a clinical trial article from the current literature. Second, have each student develop a protocol on a clinically relevant research question that is of interest to the student. These draft protocols can often be turned into protocols that are implemented. Although there is a chapter on regulatory issues, this book is not meant to replace going to the actual agencies for guidance on regulations and policies. Those differ among countries and frequently change. Rather, as the title indicates, we hope to provide the fundamentals of clinical trials ethics, design, conduct, analysis, and reporting.

The first chapter describes the rationale and phases of clinical trials. Chapter 2 covers selected ethical issues. Chapter 3 describes the questions that clinical trials seek to answer and Chap. 4 discusses the populations from which the study samples are derived. The strengths and weaknesses of various kinds of study designs, including noninferiority trials, are reviewed in Chap. 5. The process of randomization is covered in Chap. 6. In Chap. 7, we discuss the importance of and difficulties in maintaining blinding. How the sample size is estimated is covered in Chap. 8. Chapter 9 describes what constitutes the baseline measures. Chapter 10 reviews recruitment techniques and may be of special interest to investigators not having ready access to trial participants. Methods for collecting high-quality data and some common problems in data collection are included in Chap. 11. Chapters 12 and 13 focus on assessment of harm and health-related quality of life that are important clinical trial outcomes. Measures to enhance and monitor participant adherence are presented in Chap. 14. Chapter 15 reviews techniques of survival analysis. Chapter 16 presents the functions of data monitoring committees and Chap. 17 reviews methods of data monitoring. Which data should be analyzed? The authors develop this question in Chap. 18 by discussing reasons for not withdrawing participants from analysis. Topics such as subgroup analysis and meta-analysis are also addressed. Chapter 19 deals with phasing out clinical trials and Chap. 20 with reporting and interpretation of results. In Chap. 21, we present information about multicenter, including multinational, studies, which have features requiring special attention. Several points covered in Chap. 21 may also be of value to investigators conducting single center studies. Finally, selected regulatory issues, as they apply to clinical trials are reviewed in Chap. 22.

This book is a collaborative effort and is based on knowledge gained in over four decades of developing, conducting, overseeing, and analyzing data from a number of clinical trials. This experience is chiefly, but not exclusively, in trials of heart and lung diseases, AIDS, and cancer. As a consequence, many of the examples cited are based on work done in these fields. However, the principles are applicable to clinical trials in general. The reader will note that although the book contains examples that are relatively recent, others are quite old. The fundamentals of

clinical trials were developed in those older studies, and we cite them because, despite important advances, many of the basic features remain unchanged.

In the first edition, the authors had read or were familiar with much of the relevant literature on the design, conduct, and analysis of clinical trials. Today, that task would be nearly impossible as the literature over the past three and a half decades has expanded enormously. The references used in this text are not meant to be exhaustive but rather to include the literature that established the fundamentals and newer publications that support the basic concepts.

The views expressed in this book are those of the authors and do not necessarily represent the views of the institutions with which the authors have been or are affiliated.

North Bethesda, MD, USA  
 Winston-Salem, NC, USA  
 Madison, WI, USA  
 Winston-Salem, NC, USA  
 Durham, NC, USA

Lawrence M. Friedman  
 Curt D. Furberg  
 David L. DeMets  
 David M. Reboussin  
 Christopher B. Granger

## References

1. NIH Inventory of Clinical Trials: Fiscal Year 1979. Volume 1. National Institutes of Health, Division of Research Grants, Research Analysis and Evaluation Branch, Bethesda, MD.
2. Bulpitt CJ. *Randomised Controlled Clinical Trials*. The Hague: Martinus Nijhoff, 1983.
3. Pocock SJ. *Clinical Trials—A Practical Approach*. New York: John Wiley and Sons, 1983.
4. Ingelfinger JA, Mosteller F, Thibodeau LA, et al. *Biostatistics in Clinical Medicine*. New York: Macmillan, 1983.
5. Iber FL, Riley WA, Murray PJ. *Conducting Clinical Trials*. New York: Plenum, 1987.
6. Peace KE (ed.). *Statistical Issues in Drug Research and Development*. New York: Marcel Dekker, 1990.
7. Spilker B. *Guide to Clinical Trials*. New York: Raven Press, 1991.
8. Spriet A, Dupin-Spriet T, Simon P. *Methodology of Clinical Drug Trials* (2<sup>nd</sup> edition). Basel: Karger, 1994.
9. Chow S-C, Shao J. *Statistics in Drug Research: Methodologies and Recent Developments*. New York: Marcel Dekker, 2002.
10. Rosenberger WF, Lachin JM. *Randomization in Clinical Trials: Theory and Practice*. New York: Wiley, 2002.
11. Geller NL (ed.). *Advances in Clinical Trial Biostatistics*. New York: Marcel Dekker, 2003.
12. Piantadosi S. *Clinical Trials: A Methodologic Perspective* (2<sup>nd</sup> edition). New York: John Wiley and Sons, 2005.
13. Matthews JNS. *An Introduction to Randomised Controlled Clinical Trials* (2<sup>nd</sup> edition). Boca Raton: Chapman & Hall/CRC, 2006.
14. Machin D, Day S, Green S. *Textbook of Clinical Trials* (2<sup>nd</sup> edition). West Sussex: John Wiley and Sons, 2006.
15. Keech A, GebSKI V, Pike R (eds.). *Interpreting and Reporting Clinical Trials*. Sidney: Australasian Medical Publishing Company, 2007.
16. Cook TD, DeMets DL (eds.). *Introduction to Statistical Methods for Clinical Trials*. Boca Raton: Chapman & Hall/CRC, Taylor & Francis Group, LLC, 2008.

17. Machin D, Fayers P. *Randomized Clinical Trials: Design, Practice and Reporting*. Chichester, West Sussex: Wiley-Blackwell, 2010.
18. Green S, Benedetti J, Crowley J. *Clinical Trials in Oncology* (3rd edition). Boca Raton: Chapman & Hall/CRC Press, 2012.
19. Meinert CL. *Clinical Trials: Design, Conduct, and Analysis* (2<sup>nd</sup> edition). New York: Oxford University Press, 2012.
20. Hulley SB, Cummings SR, Browner WS, et al. *Designing Clinical Research* (4<sup>th</sup> edition). New York: Wolters Kluwer/Lippincott Williams & Wilkins, 2013.
21. Chow S-C, Liu J-P. *Design and Analysis of Clinical Trials: Concepts and Methodologies* (3<sup>rd</sup> edition). Hoboken, NJ: Wiley, 2014.

# Acknowledgments

Most of the ideas and concepts discussed in this book represent what we first learned during our years at the National Heart, Lung, and Blood Institute and in academia. We are indebted to many colleagues, and particularly in the case of the original three authors, to the late Dr. Max Halperin, with whom we had numerous hours of discussion for the earlier editions on theoretical and operational aspects of the design, conduct, and analysis of clinical trials.

Many have contributed to this fifth edition of the book. We appreciate the efforts of Drs. Michelle Naughton and Sally Shumaker in revising the chapter on health-related quality of life and Mr. Thomas Moore for his contributions to the chapter on assessment and reporting of harm. Also appreciated are the constructive comments of Drs. Bengt Furberg and Bradi Granger. We want to particularly acknowledge the outstanding administrative support of Donna Ashford and Catherine Dalsing. Finally, nobody deserves more credit than our families and colleagues who have unfailingly encouraged us in this effort. This is especially true of Gene, Birgitta, Kathy, Beth, and Bradi, who gave up many evenings and weekends with their spouses.

# Contents

<b>1</b>	<b>Introduction to Clinical Trials</b> . . . . .	1
	Fundamental Point . . . . .	2
	What Is a Clinical Trial? . . . . .	2
	Clinical Trial Phases . . . . .	4
	Phase I Studies . . . . .	5
	Phase II Studies . . . . .	7
	Phase III/IV Trials . . . . .	9
	Why Are Clinical Trials Needed? . . . . .	10
	Problems in the Timing of a Trial . . . . .	14
	Study Protocol . . . . .	15
	Appendices . . . . .	17
	References . . . . .	18
<b>2</b>	<b>Ethical Issues</b> . . . . .	25
	Fundamental Point . . . . .	27
	Planning and Design . . . . .	27
	Ethics Training . . . . .	27
	Does the Question Require a Clinical Trial? . . . . .	27
	Randomization . . . . .	30
	Control Group . . . . .	31
	Protection from Conflicts of Interest . . . . .	33
	Informed Consent . . . . .	34
	Conduct . . . . .	37
	Trials in Low- and Middle-Income Countries . . . . .	37
	Recruitment . . . . .	38
	Safety and Efficacy Monitoring . . . . .	39
	Early Termination for Other Than Scientific or Safety Reasons . . . . .	40
	Privacy and Confidentiality . . . . .	41
	Data Falsification . . . . .	41

Reporting . . . . .	42
Publication Bias, Suppression, and Delays . . . . .	42
Conflicts of Interest and Publication . . . . .	43
References . . . . .	43
<b>3 What Is the Question?</b> . . . . .	49
Fundamental Point . . . . .	50
Selection of the Questions . . . . .	50
Primary Question . . . . .	50
Secondary Questions Regarding Benefit . . . . .	51
Questions Regarding Harm . . . . .	52
Ancillary Questions . . . . .	53
Kinds of Trials . . . . .	54
Trials with Extensive Data Collection	
vs. Large, Simple . . . . .	54
Superiority vs. Noninferiority Trials . . . . .	55
Comparative Effectiveness Trials . . . . .	55
Intervention . . . . .	56
Response Variables . . . . .	57
Kinds of Response Variables . . . . .	57
Specifying the Question . . . . .	60
Biomarkers and Surrogate Response	
Variables . . . . .	62
Changing the Question . . . . .	65
General Comments . . . . .	66
References . . . . .	67
<b>4 Study Population</b> . . . . .	73
Fundamental Point . . . . .	73
Definition of Study Population . . . . .	74
Considerations in Defining the Study	
Population . . . . .	75
Potential for Benefit . . . . .	76
High Likelihood of Showing Benefit . . . . .	78
Avoiding Adverse Effects . . . . .	80
Competing Risk . . . . .	81
Avoiding Poor Adherers . . . . .	81
Pharmacogenetics . . . . .	82
Generalization . . . . .	83
Recruitment . . . . .	85
References . . . . .	86
<b>5 Basic Study Design</b> . . . . .	89
Fundamental Point . . . . .	90
Overview . . . . .	90
Randomized Control Trials . . . . .	92

Nonrandomized Concurrent Control Studies . . . . .	94
Historical Controls and Databases . . . . .	95
Strengths of Historical Control Studies . . . . .	95
Limitations of Historical Control Studies . . . . .	96
Role of Historical Controls . . . . .	100
Cross-Over Designs . . . . .	102
Withdrawal Studies . . . . .	103
Factorial Design . . . . .	104
Group Allocation Designs . . . . .	106
Hybrid Designs . . . . .	107
Large, Simple and Pragmatic Clinical Trials . . . . .	107
Studies of Equivalency and Noninferiority . . . . .	109
Adaptive Designs . . . . .	114
References . . . . .	115
<b>6 The Randomization Process . . . . .</b>	<b>123</b>
Fundamental Point . . . . .	123
Fixed Allocation Randomization . . . . .	124
Simple Randomization . . . . .	125
Blocked Randomization . . . . .	126
Stratified Randomization . . . . .	128
Adaptive Randomization Procedures . . . . .	131
Baseline Adaptive Randomization Procedures . . . . .	132
Minimization . . . . .	133
Response Adaptive Randomization . . . . .	135
Mechanics of Randomization . . . . .	137
Recommendations . . . . .	139
Appendix: Adaptive Randomization Algorithm . . . . .	139
References . . . . .	141
<b>7 Blinding . . . . .</b>	<b>147</b>
Fundamental Point . . . . .	148
Who Is Blinded? . . . . .	148
Types of Blinding . . . . .	148
Unblinded . . . . .	148
Single-Blind . . . . .	150
Double-Blind . . . . .	151
Triple-Blind . . . . .	153
Protecting the Double-Blind Design . . . . .	154
Matching of Drugs . . . . .	155
Coding of Drugs . . . . .	157
Official Unblinding . . . . .	158
Inadvertent Unblinding . . . . .	159
Assessment and Reporting of Blinding . . . . .	160
Debriefing of Participants . . . . .	161
References . . . . .	162

**8 Sample Size** . . . . . 165

    Fundamental Point . . . . . 166

    Statistical Concepts . . . . . 167

    Dichotomous Response Variables . . . . . 171

        Two Independent Samples . . . . . 171

        Paired Dichotomous Response . . . . . 177

        Adjusting Sample Size to Compensate for Nonadherence . . . . . 178

    Sample Size Calculations for Continuous Response Variables . . . . . 179

        Two Independent Samples . . . . . 180

        Paired Data . . . . . 181

    Sample Size for Repeated Measures . . . . . 183

    Sample Size Calculations for “Time to Failure” . . . . . 184

    Sample Size for Testing “Equivalency” or Noninferiority of Interventions . . . . . 188

    Sample Size for Cluster Randomization . . . . . 189

    Multiple Response Variables . . . . . 192

    Estimating Sample Size Parameters . . . . . 193

    References . . . . . 195

**9 Baseline Assessment** . . . . . 201

    Fundamental Point . . . . . 201

    Uses of Baseline Data . . . . . 201

        Description of Trial Participants . . . . . 201

        Baseline Comparability . . . . . 202

        Controlling for Imbalances in the Analysis . . . . . 204

        Subgrouping . . . . . 205

    What Constitutes a True Baseline Measurement? . . . . . 207

        Screening for Participants . . . . . 207

        Regression Toward the Mean . . . . . 208

        Interim Events . . . . . 210

        Uncertainty About Qualifying Diagnosis . . . . . 210

        Contamination of the Intervention . . . . . 211

    Changes of Baseline Measurement . . . . . 212

    References . . . . . 213

**10 Recruitment of Study Participants** . . . . . 215

    Fundamental Point . . . . . 215

    Considerations Before Participant Enrollment . . . . . 216

        Selection of Study Sample . . . . . 216

        Common Recruitment Problems . . . . . 217

        Planning . . . . . 219

        Recruitment Sources . . . . . 221

    Conduct . . . . . 223

    Monitoring . . . . . 225

    Approaches to Lagging Recruitment . . . . . 229

    References . . . . . 230

**11 Data Collection and Quality Control** . . . . . 233

    Fundamental Point . . . . . 234

    Problems in Data Collection . . . . . 235

        Major Types . . . . . 235

    Minimizing Poor Quality Data . . . . . 238

        Design of Protocol and Manual . . . . . 238

        Development of Forms and Data Entry Tools . . . . . 239

        Training and Certification . . . . . 239

        Pretesting . . . . . 241

        Techniques to Reduce Variability Including Central  
        Adjudication of Events . . . . . 241

        Data Entry . . . . . 243

        Electronic Source Data . . . . . 243

    Quality Monitoring . . . . . 244

        Monitoring of Data . . . . . 246

        Monitoring of Procedures . . . . . 246

        Monitoring of Drug Handling . . . . . 247

        Audits . . . . . 248

    References . . . . . 250

**12 Assessment and Reporting of Harm** . . . . . 255

    Fundamental Point . . . . . 256

    Assessment of Harm . . . . . 256

        Strengths . . . . . 256

        Limitations . . . . . 257

        Identification of Harm in Clinical Trials . . . . . 259

    Classification of Adverse Events . . . . . 260

    Ascertainment . . . . . 262

        Prespecified Adverse Events . . . . . 263

        Characteristics of Adverse Events . . . . . 264

        Length of Follow-up . . . . . 264

    Analyzing Adverse Events . . . . . 266

        Standard Reporting . . . . . 266

        Prespecified Analysis . . . . . 267

        Post Hoc Analysis . . . . . 267

        Meta-analysis . . . . . 268

    Reporting of Harm . . . . . 269

    Scientific Journal Publication . . . . . 271

    Regulatory Considerations . . . . . 272

    Recommendations for Assessing and Reporting Harm . . . . . 273

    References . . . . . 274

**13 Assessment of Health Related Quality of Life** . . . . . 279

    Fundamental Point . . . . . 279

    Types of HRQL Measures . . . . . 280

Primary Measures . . . . .	280
Additional Measures . . . . .	281
Uses of HRQL Measures . . . . .	282
Methodological Issues . . . . .	284
Design Issues . . . . .	284
Study Population . . . . .	285
Type of Intervention . . . . .	285
Frequency of Assessment (Acute Versus Chronic) . . . . .	286
Protocol Considerations . . . . .	287
Modifying and Mediating Factors . . . . .	288
Selection of HRQL Instruments . . . . .	288
Types of Measures . . . . .	289
Scoring of HRQL Measures . . . . .	290
Determining the Significance of HRQL Measures . . . . .	290
Utility Measures/Preference Scaling and Comparative Effectiveness Research . . . . .	291
References . . . . .	292
<b>14 Participant Adherence . . . . .</b>	<b>297</b>
Fundamental Point . . . . .	298
Definitions . . . . .	298
Medication Adherence . . . . .	299
Considerations Before Participant Enrollment . . . . .	300
Design Factors . . . . .	300
Participant Factors . . . . .	302
Maintaining Good Participant Adherence . . . . .	306
Adherence Monitoring . . . . .	311
Dealing with Low Adherence . . . . .	314
Special Populations . . . . .	315
References . . . . .	315
<b>15 Survival Analysis . . . . .</b>	<b>319</b>
Fundamental Point . . . . .	319
Estimation of the Survival Curve . . . . .	320
Cutler-Ederer Estimate . . . . .	324
Kaplan-Meier Estimate . . . . .	324
Comparison of Two Survival Curves . . . . .	328
Point-by-Point Comparison . . . . .	329
Comparison of Median Survival Times . . . . .	329
Total Curve Comparison . . . . .	330
Generalizations . . . . .	335
Covariate Adjusted Analysis . . . . .	337
References . . . . .	340

<b>16</b>	<b>Monitoring Committee Structure and Function</b> . . . . .	343
	Fundamental Point . . . . .	346
	Monitoring Committee . . . . .	346
	Repeated Testing for Significance . . . . .	350
	Decision for Early Termination . . . . .	352
	Decision to Extend a Trial . . . . .	363
	Accelerated Approval Paradigm . . . . .	367
	References . . . . .	368
<b>17</b>	<b>Statistical Methods Used in Interim Monitoring</b> . . . . .	373
	Fundamental Point . . . . .	373
	Classical Sequential Methods . . . . .	374
	Group Sequential Methods . . . . .	375
	Flexible Group Sequential Procedures:	
	Alpha Spending Functions . . . . .	378
	Applications of Group Sequential Boundaries . . . . .	381
	Asymmetric Boundaries . . . . .	384
	Curtailed Sampling and Conditional	
	Power Procedures . . . . .	386
	Other Approaches . . . . .	391
	Trend Adaptive Designs and Sample Size Adjustments . . . . .	392
	References . . . . .	395
<b>18</b>	<b>Issues in Data Analysis</b> . . . . .	403
	Fundamental Point . . . . .	404
	Which Participants Should Be Analyzed? . . . . .	404
	Ineligibility . . . . .	406
	Nonadherence . . . . .	410
	Missing or Poor Quality Data . . . . .	414
	Competing Events . . . . .	421
	Composite Outcomes . . . . .	422
	Covariate Adjustment . . . . .	424
	Surrogates as a Covariate . . . . .	425
	Baseline Variables as Covariates . . . . .	428
	Subgroup Analyses . . . . .	431
	Not Counting Some Events . . . . .	438
	Comparison of Multiple Variables . . . . .	439
	Use of Cutpoints . . . . .	440
	Noninferiority Trial Analysis . . . . .	442
	Analysis Following Trend Adaptive Designs . . . . .	444
	Meta-analysis of Multiple Studies . . . . .	445
	Rationale and Issues . . . . .	445
	Statistical Methods . . . . .	449
	Analysis for Harmful Effects . . . . .	451
	References . . . . .	453

<b>19</b>	<b>Closeout</b> . . . . .	463
	Fundamental Point . . . . .	463
	Termination Procedures . . . . .	463
	Planning . . . . .	463
	Scheduling of Closeout Visits . . . . .	464
	Final Response Ascertainment . . . . .	465
	Transfer of Post-trial Care . . . . .	468
	Data and Other Study Material . . . . .	469
	Cleanup and Verification . . . . .	469
	Storage . . . . .	470
	Dissemination of Results . . . . .	471
	Post Study Follow-up . . . . .	473
	References . . . . .	475
<b>20</b>	<b>Reporting and Interpreting of Results</b> . . . . .	479
	Fundamental Point . . . . .	480
	Guidelines for Reporting . . . . .	480
	Authorship . . . . .	482
	Duplicate Publication . . . . .	483
	Disclosure of Conflict of Interest . . . . .	483
	Presentation of Data . . . . .	483
	Interpretation . . . . .	484
	Publication Bias . . . . .	485
	Did the Trial Work as Planned? . . . . .	487
	Baseline Comparability . . . . .	487
	Blinding . . . . .	487
	Adherence and Concomitant Treatment . . . . .	488
	What Are the Limitations? . . . . .	488
	What Kinds of Analyses? . . . . .	489
	How Do the Findings Compare with Those from Other Studies? . . . . .	491
	What Are the Clinical Implications of the Findings? . . . . .	492
	Data Sharing . . . . .	493
	References . . . . .	494
<b>21</b>	<b>Multicenter Trials</b> . . . . .	501
	Fundamental Point . . . . .	502
	Reasons for Multicenter Trials . . . . .	502
	Conduct of Multicenter Trials . . . . .	504
	Globalization of Trials . . . . .	511
	Large, Simple Trials . . . . .	514
	References . . . . .	515
<b>22</b>	<b>Regulatory Issues</b> . . . . .	519
	Fundamental Point . . . . .	520
	Background . . . . .	521

Overview . . . . .	521
History . . . . .	521
Regulatory Requirements . . . . .	523
Trial Phases . . . . .	523
Pretrial Requirements . . . . .	525
Conduct . . . . .	526
Interventions: Drugs . . . . .	528
Interventions: Devices . . . . .	529
Interventions: Biologics . . . . .	532
Post-trial Requirements . . . . .	533
Documents for FDA submission . . . . .	534
Advisory Committee Meeting . . . . .	535
Post-approval Issues and Postmarketing Investigations . . . . .	535
Key Links . . . . .	537
International Conference on Harmonisation . . . . .	537
U.S. Food and Drug Administration . . . . .	537
European Medicines Agency . . . . .	538
Health Canada . . . . .	538
Pharmaceuticals and Medical Devices Agency, Japan . . . . .	538
Bioethics Resources . . . . .	538
References . . . . .	538
<b>Erratum . . . . .</b>	<b>E1</b>
<b>Index . . . . .</b>	<b>543</b>